BR112022001492A2 - Anticorpo anti-il17a humanizado e uso do mesmo - Google Patents
Anticorpo anti-il17a humanizado e uso do mesmoInfo
- Publication number
- BR112022001492A2 BR112022001492A2 BR112022001492A BR112022001492A BR112022001492A2 BR 112022001492 A2 BR112022001492 A2 BR 112022001492A2 BR 112022001492 A BR112022001492 A BR 112022001492A BR 112022001492 A BR112022001492 A BR 112022001492A BR 112022001492 A2 BR112022001492 A2 BR 112022001492A2
- Authority
- BR
- Brazil
- Prior art keywords
- il17a
- antibody
- humanized
- ability
- present
- Prior art date
Links
- 239000003814 drug Substances 0.000 abstract 3
- 229940079593 drug Drugs 0.000 abstract 3
- 201000004681 Psoriasis Diseases 0.000 abstract 2
- 150000007523 nucleic acids Chemical group 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 102000004127 Cytokines Human genes 0.000 abstract 1
- 108090000695 Cytokines Proteins 0.000 abstract 1
- 241000282567 Macaca fascicularis Species 0.000 abstract 1
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
- 238000010521 absorption reaction Methods 0.000 abstract 1
- 210000002950 fibroblast Anatomy 0.000 abstract 1
- 238000009169 immunotherapy Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 238000010172 mouse model Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 230000028327 secretion Effects 0.000 abstract 1
- 238000010254 subcutaneous injection Methods 0.000 abstract 1
- 239000007929 subcutaneous injection Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Dermatology (AREA)
- Transplantation (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Abstract
anticorpo anti-il17a humanizado e uso do mesmo. a presente invenção pertence ao campo de imunoterapia de doenças autoimunes e refere-se a um anticorpo monoclonal humanizado que se liga a il17a. a presente invenção revela uma sequência de ácidos nucleicos que codifica o dito anticorpo (que inclui regiões variáveis de cadeia pesada/leve), um vetor que contém as ditas sequências de ácidos nucleicos, uma composição farmacêutica e um kit. o dito anticorpo monoclonal tem capacidade de se ligar especificamente à proteína il17a com alta afinidade, tem uma forte capacidade de bloquear a ligação de il17a, il17a/f ao il17ra receptor. em comparação a fármacos comparáveis, o dito anticorpo tem capacidade superior ou equivalente de bloquear secreção de citocina inflamatória induzida por il17a e il17a/f de fibroblastos epidérmicos humanos hff; em um modelo de psoríase de camundongo, o dito anticorpo também mostrou eficácia in vivo significativamente melhor do que fármacos comparáveis, e a administração do dito anticorpo reduziu significativamente pontuações de pasi; no estudo de eficácia de macaco cinomolgo, o dito anticorpo humanizado demonstrou farmacocinética superior, incluindo rápida absorção após injeção subcutânea, longa meia-vida e melhor exposição a fármaco, etc., criando bases para ciclos de dosagens maiores. o anticorpo monoclonal humanizado da presente invenção pode ser usado para o tratamento de psoríase, etc.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910682988 | 2019-07-26 | ||
PCT/CN2020/104448 WO2021018035A1 (zh) | 2019-07-26 | 2020-07-24 | 人源化抗il17a抗体及其应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112022001492A2 true BR112022001492A2 (pt) | 2022-03-22 |
Family
ID=74230189
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112022001492A BR112022001492A2 (pt) | 2019-07-26 | 2020-07-24 | Anticorpo anti-il17a humanizado e uso do mesmo |
Country Status (10)
Country | Link |
---|---|
US (1) | US20220144936A1 (pt) |
EP (1) | EP4036113A4 (pt) |
JP (1) | JP7214921B2 (pt) |
KR (1) | KR20220071179A (pt) |
CN (1) | CN114286827B (pt) |
AU (1) | AU2020322569B2 (pt) |
BR (1) | BR112022001492A2 (pt) |
CA (1) | CA3148491C (pt) |
MX (1) | MX2022001068A (pt) |
WO (1) | WO2021018035A1 (pt) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117106083A (zh) * | 2022-03-25 | 2023-11-24 | 南京融捷康生物科技有限公司 | 一种抗il-17a的单域抗体及其用途 |
WO2024167879A1 (en) * | 2023-02-06 | 2024-08-15 | Biohaven Therapeutics Ltd. | Bifunctional molecules to target degradation of interleukin 17a (il-17a) |
CN117843804B (zh) * | 2023-12-29 | 2024-08-20 | 北京贝来药业有限公司 | 单域抗体串联分子及其序列、产品、制备和应用 |
CN117843801B (zh) * | 2023-12-29 | 2024-08-02 | 北京贝来药业有限公司 | 以白介素家族成员为靶点的新型抗体以及下游产品 |
CN118206654B (zh) * | 2024-03-05 | 2024-09-20 | 北京贝来药业有限公司 | 用于疾病治疗的新型抗体及其产品和应用 |
CN117866902B (zh) * | 2024-03-12 | 2024-06-04 | 北京贝来生物科技有限公司 | 具有抗il-17a活性的基因修饰干细胞及其制备方法以及药物组合物 |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4510245A (en) | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
EP0940468A1 (en) | 1991-06-14 | 1999-09-08 | Genentech, Inc. | Humanized antibody variable domain |
DK1068241T3 (da) | 1998-04-02 | 2008-02-04 | Genentech Inc | Antistofvarianter og fragmenter deraf |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
GB0417487D0 (en) | 2004-08-05 | 2004-09-08 | Novartis Ag | Organic compound |
ES2672221T3 (es) | 2005-12-13 | 2018-06-13 | Eli Lilly And Company | Anticuerpos anti IL-17 |
WO2009147362A1 (en) * | 2008-06-03 | 2009-12-10 | Imperial Innovations Limited | Method of rheumatoid arthritis treatment |
PT2953969T (pt) * | 2013-02-08 | 2019-12-03 | Novartis Ag | Anticorpos anti-il-17a e utilização dos mesmos no tratamento de distúrbios autoimunes e inflamatórios |
WO2014161570A1 (en) * | 2013-04-03 | 2014-10-09 | Roche Glycart Ag | Antibodies against human il17 and uses thereof |
JP6255099B2 (ja) | 2013-08-15 | 2017-12-27 | ノバルティス アーゲー | Il−17アンタゴニストを使用して汎発性膿疱性乾癬(gpp)を処置する方法 |
CA3065553A1 (en) * | 2017-06-18 | 2018-12-27 | Kindred Biosciences, Inc. | Il17a antibodies and antagonists for veterinary use |
CA3073597A1 (en) | 2017-08-23 | 2019-02-28 | Eli Lilly And Company | Treatment of genital psoriasis |
US20200277369A1 (en) | 2017-11-20 | 2020-09-03 | Novartis Ag | Method of treating hidradentitis suppurativa with il-17 antagonists |
CN109679920B (zh) * | 2018-12-26 | 2019-11-22 | 北京贝来生物科技有限公司 | 一种表达il-17a信号通路阻断剂的间充质干细胞 |
CN110003337B (zh) * | 2019-04-12 | 2023-05-09 | 深圳普瑞金生物药业股份有限公司 | Il17ra单域抗体、核酸及试剂盒 |
-
2020
- 2020-07-24 EP EP20846348.9A patent/EP4036113A4/en active Pending
- 2020-07-24 BR BR112022001492A patent/BR112022001492A2/pt unknown
- 2020-07-24 KR KR1020227005577A patent/KR20220071179A/ko unknown
- 2020-07-24 WO PCT/CN2020/104448 patent/WO2021018035A1/zh unknown
- 2020-07-24 CA CA3148491A patent/CA3148491C/en active Active
- 2020-07-24 MX MX2022001068A patent/MX2022001068A/es unknown
- 2020-07-24 AU AU2020322569A patent/AU2020322569B2/en active Active
- 2020-07-24 JP JP2022505484A patent/JP7214921B2/ja active Active
- 2020-07-24 CN CN202080050601.7A patent/CN114286827B/zh active Active
-
2022
- 2022-01-26 US US17/584,766 patent/US20220144936A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
KR20220071179A (ko) | 2022-05-31 |
MX2022001068A (es) | 2022-02-14 |
JP2022535151A (ja) | 2022-08-04 |
WO2021018035A1 (zh) | 2021-02-04 |
CA3148491C (en) | 2023-08-01 |
EP4036113A1 (en) | 2022-08-03 |
US20220144936A1 (en) | 2022-05-12 |
CA3148491A1 (en) | 2021-02-04 |
AU2020322569A1 (en) | 2022-02-17 |
AU2020322569B2 (en) | 2024-10-24 |
CN114286827A (zh) | 2022-04-05 |
EP4036113A4 (en) | 2023-01-18 |
JP7214921B2 (ja) | 2023-01-30 |
CN114286827B (zh) | 2024-01-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112022001492A2 (pt) | Anticorpo anti-il17a humanizado e uso do mesmo | |
ES2579768T3 (es) | Anticuerpos anti-KIR, formulaciones y usos de los mismos | |
AU2015370522B2 (en) | Pharmaceutical products and stable liquid compositions of IL-17 antibodies | |
BRPI0905076B8 (pt) | anticorpo anti-receptor de il-6, gene e composição farmacêutica compreendendo o mesmo | |
AU2017351183B2 (en) | Anti-IL-33 antibodies and uses thereof | |
HRP20110334T1 (hr) | PROTUTIJELA SPECIFIČNA ZA TGF-ß1 | |
EA201992765A1 (ru) | Белки на основе антител с привитым цитокином и способы их применения в лечении рака | |
EP3689370A1 (en) | Anti-gdf15 antibodies | |
JP2018507202A (ja) | モノクローナル抗体のための安定的な液体製剤 | |
BRPI0715660B8 (pt) | anticorpo isolado que se liga a il-31 humana, e, uso de um anticorpo monoclonal | |
BR112016013347A8 (pt) | anticorpo monoclonal humano neutralizante anti-il-33,composição farmacêutica,inibidor da expressão de citocinas,epitopo,molécula de ácido nucleico,vetor,célula hospedeira,método de produção e uso dos mesmos. | |
RU2011144312A (ru) | БИСПЕЦИФИЧЕСКИЕ АНТИ-ErbB-3/АНТИ-С-МЕТ АНТИТЕЛА | |
BRPI0314038B8 (pt) | anticorpo humano isolado, molécula de ácido nucleico isolada, vetor, uso de um anticorpo, e, composição farmacêutica | |
CN106039306A (zh) | 使用针对TNFα的单结构域抗体治疗免疫病症的方法 | |
BR112016020643A2 (pt) | anticorpos específicos para receptor de fator de crescimento semelhante à insulina tipo 1 e uso dos mesmos | |
JP2019517508A5 (pt) | ||
BR112021023501A2 (pt) | Formulações estabilizadas contendo anticorpos anti-angptl3 | |
JP2018515493A5 (pt) | ||
CL2023003218A1 (es) | Polipéptidos de unión a antígeno bma031 mejorados | |
BR112020006248A8 (pt) | Anticorpo anti-bcma com alta afinidade para bcma, polinucleotídeo, vetor de expressão, célula hospedeira, método para produção do dito anticorpo, composição farmacêutica compreendendo o mesmo e uso do anticorpo para prevenção ou tratamento de câncer | |
JPWO2016133197A1 (ja) | Fc融合高親和性IgE受容体α鎖 | |
TW201439118A (zh) | Bmp-6抗體 | |
ES2992409T3 (es) | Métodos de tratamiento de la psoriasis en placas de nueva aparición usando antagonistas de IL-17 | |
JP2019520316A5 (pt) | ||
BR112021018727A2 (pt) | Formulações estabilizadas que contêm anticorpos anti il 33 |